tetrahydrozoline/zinc sulfate/hypromellose ophthalmic (Rohto Ice, Rohto Relief)
Classes: Ophthalmic Lubricants
- Dosing and uses of Rohto Ice, Rohto Relief (tetrahydrozoline/zinc sulfate/hypromellose ophthalmic)
- Rohto Ice, Rohto Relief (tetrahydrozoline/zinc sulfate/hypromellose ophthalmic) adverse (side) effects
- Warnings
- Pregnancy
- Pharmacology of Rohto Ice, Rohto Relief (tetrahydrozoline/zinc sulfate/hypromellose ophthalmic)
Dosing and uses of Rohto Ice, Rohto Relief (tetrahydrozoline/zinc sulfate/hypromellose ophthalmic)
Adult dosage forms and strengths
tetrahydrozoline/zinc sulfate/hypromellose
ophthalmic solution
- 0.05%/0.25%/0.2%
Ocular Redness & Irritation
Indicated to temporarily relieve discomfort due to minor ophthalmic irritations and redness
1-2 gtt in each eye PRN; not to exceed 4 doses/day
Administration
Do not touch tip of container to any surface to avoid contamination
Replace cap after each use
Do not use if solution changes color or becomes cloudy
Remove contact lenses before use
Pediatric dosage forms and strengths
tetrahydrozoline/zinc sulfate/hypromellose
ophthalmic solution
- 0.05%/0.25%/0.2%
Ocular Redness & Irritation
Indicated to temporarily relieve discomfort due to minor ophthalmic irritations and redness
1-2 gtt in each eye PRN; not to exceed 4 doses/day
Administration
Do not touch tip of container to any surface to avoid contamination
Replace cap after each use
Do not use if solution changes color or becomes cloudy
Remove contact lenses before use
Rohto Ice, Rohto Relief (tetrahydrozoline/zinc sulfate/hypromellose ophthalmic) adverse (side) effects
Frequency not defined
Increased IOp
Transient blurred vision
Transient ocular dryness
Transient ocular burning/stinging
Rebound conjunctival hyperemia
Warnings
Contraindications
Hypersensitivity
Cautions
Discontinue use if the following occurs
- Eye pain
- Vision changes
- Unresolved redness or irritation
- Condition worsens or lasts >72 hr
Tetrahydrozoline
- Narrow angle glaucoma
- May cause temporary mydriasis
- Use caution in hypertension, coronary artery disease, diabetes, and hyperthyroidism
Pregnancy and lactation
Pregnancy category: B
Lactation: Unknown if distributed in human breast milk
Pregnant or breastfeeding patients should seek advice of health professional before using OTC drugs
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Rohto Ice, Rohto Relief (tetrahydrozoline/zinc sulfate/hypromellose ophthalmic)
Mechanism of action
Tetrahydrozoline: Ophthalmic decongestant; reduces redness; stimulates alpha-adrenergic receptors in the arterioles of the conjunctiva; produces vasoconstriction; may produce mydriasis when applied to the conjunctiva, but this effect is usually minimal with the concentrations used as ocular decongestants
Zinc sulfate: Provides astringent effects to dry mucus and relieve irritation
Hypromellose: Demulcent that lubricates eye surface